Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Division of Oral Science for Health Promotion, Niigata University Graduate School of Medical and Dental Sciences, 5274 Gakkocho 2-ban-cho, Chuo-ku, Niigata 951-8514, Japan.
Nat Immunol. 2014 Nov;15(11):1055-1063. doi: 10.1038/ni.3009. Epub 2014 Oct 5.
TRPV1 is a Ca(2+)-permeable channel studied mostly as a pain receptor in sensory neurons. However, its role in other cell types is poorly understood. Here we found that TRPV1 was functionally expressed in CD4(+) T cells, where it acted as a non-store-operated Ca(2+) channel and contributed to T cell antigen receptor (TCR)-induced Ca(2+) influx, TCR signaling and T cell activation. In models of T cell-mediated colitis, TRPV1 promoted colitogenic T cell responses and intestinal inflammation. Furthermore, genetic and pharmacological inhibition of TRPV1 in human CD4(+) T cells recapitulated the phenotype of mouse Trpv1(-/-) CD4(+) T cells. Our findings suggest that inhibition of TRPV1 could represent a new therapeutic strategy for restraining proinflammatory T cell responses.
瞬时受体电位香草酸亚型 1(TRPV1)是一种钙(Ca2+)通透性通道,主要作为感觉神经元中的疼痛受体进行研究。然而,其在其他细胞类型中的作用尚未被充分了解。在这里,我们发现 TRPV1 在 CD4+T 细胞中具有功能性表达,在 CD4+T 细胞中,它充当非储存操纵的 Ca2+通道,并有助于 T 细胞抗原受体(TCR)诱导的 Ca2+内流、TCR 信号转导和 T 细胞激活。在 T 细胞介导的结肠炎模型中,TRPV1 促进致结肠炎 T 细胞反应和肠道炎症。此外,在人类 CD4+T 细胞中,TRPV1 的基因和药理学抑制再现了小鼠 Trpv1(-/-)CD4+T 细胞的表型。我们的研究结果表明,抑制 TRPV1 可能代表一种新的治疗策略,用于抑制促炎 T 细胞反应。